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background
 
There is evidence that chronic inflammation may promote atherosclerotic disease. We
tested the hypothesis that acute infection and vaccination increase the short-term risk
of vascular events.
 
methods
 
We undertook within-person comparisons, using the case-series method, to study the
risks of myocardial infarction and stroke after common vaccinations and naturally oc-
curring infections. The study was based on the United Kingdom General Practice Re-
search Database, which contains computerized medical records of more than 5 million
patients.
 
results
 
A total of 20,486 persons with a first myocardial infarction and 19,063 persons with a
first stroke who received influenza vaccine were included in the analysis. There was no
increase in the risk of myocardial infarction or stroke in the period after influenza, tet-
anus, or pneumococcal vaccination. However, the risks of both events were substan-
tially higher after a diagnosis of systemic respiratory tract infection and were highest
during the first three days (incidence ratio for myocardial infarction, 4.95; 95 percent
confidence interval, 4.43 to 5.53; incidence ratio for stroke, 3.19; 95 percent confi-
dence interval, 2.81 to 3.62). The risks then gradually fell during the following weeks.
The risks were raised significantly but to a lesser degree after a diagnosis of urinary
tract infection. The findings for recurrent myocardial infarctions and stroke were sim-
ilar to those for first events.
 
conclusions
 
Our findings provide support for the concept that acute infections are associated with
a transient increase in the risk of vascular events. By contrast, influenza, tetanus, and
pneumococcal vaccinations do not produce a detectable increase in the risk of vascular
events.
abstract
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ystemic inflammation and infec-
 
tions accelerate atherogenesis in animals,
 
1
 
and circulating markers of inflammation,
such as C-reactive protein, predict the risk of vas-
cular events in humans.
 
2,3
 
 However, systemic in-
flammation is not a constant but varies in response
to infections or to other proinflammatory stimuli.
Such intermittent changes may be linked to an in-
crease in the risk of vascular events. Indeed, inflam-
matory markers predict the outcome in acute vas-
cular events
 
4,5
 
; an increased leukocyte count may
herald a short period of increased risk of stroke
 
6
 
;
and several small studies have suggested that there
may be a transient increase in the risk of a myocar-
dial infarction after infection.
 
7-12
 
The mechanisms by which acute inflammation
may affect the risk of vascular events are uncertain
but may include endothelial dysfunction. Such dys-
function is a feature of the increased risk induced
by conventional risk factors,
 
13,14
 
 and in an experi-
mental model, the vaccination of healthy volun-
teers induced a short-lived inflammation that was
associated with profound suppression of endothe-
lium-dependent relaxation.
 
15
 
 If the likelihood of a
vascular event is related to variations in the under-
lying inflammatory state and endothelial function,
many naturally occurring common infections or
even vaccination could be associated with a short-
lived increase in the event rate. To test this hy-
pothesis, we studied the incidence of myocardial
infarction and stroke after influenza and other vac-
cinations or after naturally occurring infections, us-
ing the United Kingdom General Practice Research
Database (GPRD) and the self-controlled case-series
method.
 
16
 
database
 
The GPRD has been described in detail elsewhere.
 
17
 
It is the largest source of continuous data on ill-
ness and prescribing habits in the United King-
dom.
 
17
 
 The database is representative of all prac-
tices in England and Wales in terms of geographic
distribution and size, and the age and sex distri-
butions of the population included in it are simi-
lar to those of the whole population of the United
Kingdom.
 
18
 
 The information obtained for the da-
tabase is anonymous. We obtained approval for our
study from the scientific and ethics advisory group
of the GPRD.
 
participants
 
The source population was all patients who were
registered for at least one year with a general prac-
tice that contributed to the GPRD between 1987 and
2001 (i.e., a total of 5,767,499 people from 687 gen-
eral practices). The patients had received one or two
new diagnoses of myocardial infarction or stroke
during the period of at least six months after the
start of their follow-up in the GPRD. The events doc-
umented during the first six months were excluded
because of the possibility that they had occurred be-
fore the patient joined the GPRD and had been re-
corded retrospectively. We did not differentiate
between ischemic and hemorrhagic stroke, because
such differentiation has been shown to be unreli-
able with the use of the GPRD.
 
19
 
 Patients were ex-
cluded if they were younger than 18 years of age at
the time of a first myocardial infarction or stroke
recorded in the GPRD or if the data in their medical
records indicated that the vascular event was likely
to have been recorded retrospectively. Examples of
retrospectively recorded data include the date of a
myocardial infarction or stroke that was the same
as the recorded date of other medical events on the
date of a new-patient or well-person visit, discharge
from the hospital, or a postmortem report or crema-
tion certificate.
 
exposure
 
Data were extracted on vaccinations against influ-
enza, tetanus, and pneumococcus. Some patients
had multiple records within a few days of one an-
other for the same vaccination, indicating that the
recorded date of the vaccination was inaccurate.
Therefore, for our study, vaccinated persons were
restricted to those for whom an influenza vaccina-
tion was recorded on a single day within the vacci-
nation season (September 1 to March 31), tetanus
vaccinations were received at least three months
apart, or a single pneumococcal vaccination was re-
corded. Data were also extracted on acute urinary
tract infections and acute systemic respiratory tract
infections such as pneumonia, acute bronchitis,
“chest infections,” and influenza.
 
case-series method
 
Because vaccinated and unvaccinated persons and
those with diagnosed infection and those without it
differ in ways that are difficult to measure and con-
trol for, we undertook within-person comparisons
using the case-series method
 
16,20
 
 in a population of
s
methods
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persons who had the outcome of interest. We de-
rived measures of the relative incidence of events
within defined intervals after an exposure as com-
pared with all other observed time periods for each
person.
 
21
 
 The null hypothesis was that vascular-
event rates remain constant from day to day and are
not affected by an acute exposure to vaccination or
infection. The period of exposure was defined as ex-
tending up to 91 days after the inflammatory expo-
sure and was subdivided into periods of 1 through
3 days, 4 through 7 days, 8 through 14 days, 15
through 28 days, and 29 through 91 days after the
exposure. All other observation time was taken as
the baseline period (i.e., without exposure).
Vascular events recorded on the same day as a
vaccination or an infection were excluded from the
baseline period, because these events may have been
recorded retrospectively, when the patient attended
the general practice for another reason, as shown in
a previous study.
 
22
 
 For participants who were ex-
posed to a vaccine or an infection more than once
during the observation period, each exposure was
followed by a 91-day period in which the partici-
pants were at risk. This method and the time inter-
vals used are illustrated in Figure 1. Incidence ratios
were calculated for events occurring within each
stratum of the period of exposure as compared with
the baseline periods.
 
outcome measures
 
We performed separate analyses for the type of event
(myocardial infarction or stroke), whether the event
was the first of its type or a subsequent event, and
the type of inflammatory exposure. A recurrent event
was defined as either the first occurrence of the
event during the observation period for a partici-
pant who had had the same type of event before the
start of the observation period or the second of two
events that both occurred within the observation
period for a participant with no history of such an
event. The baseline risk of myocardial infarction or
stroke is higher among persons who have had a vas-
cular event. Therefore, the observation period for a
recurrent event was restricted to the time after the
first event had occurred — either beginning six
months after the start of observation of the partici-
pant in the GPRD (for the first occurrence of an
event during the observation period for a partici-
pant who had had the same type of event before the
start of the observation period) or beginning with
the date of the first event within the observation pe-
riod (for the second of two events that occurred
within the observation period).
The exception to these starting dates was influ-
enza vaccination. One of the indications for admin-
istration of this vaccine is preexisting cardiovascular
disease, so that the probability of receiving influen-
za vaccination is itself associated with the risk of
vascular events. To ensure that during the observa-
tion period there was minimal variation in the op-
portunity to be vaccinated, the observation period
used in the analysis with regard to influenza vacci-
nation did not include the time before a participant’s
first influenza vaccination.
 
Figure 1. A Single Participant Exposed Twice to an Inflammatory Stimulus.
 
As shown in this example, the effect of each inflammatory stimulus was analyzed separately for the outcome of myocar-
dial infarction or stroke. All study participants included in a particular analysis had at least one exposure to the stimulus, 
either infection or vaccination, and had at least one vascular event. Risk periods were defined as 91-day periods (not drawn 
to scale) after a particular exposure, which were divided into days 1 through 3, 4 through 7, 8 through 14, 15 through 28, 
and 29 through 91. The length of the baseline periods varied for each participant.
Day of exposure
Start End 
Day of exposure
Baseline period Risk period
Time
91
Days
91
Days
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age, time, and secondary analyses
 
Age was controlled for in five-year age groups, and
the analysis was repeated with the use of two-year
age groups to assess whether finer stratification af-
fected the results. In a case-series analysis, partici-
pants who are not exposed to a stimulus at any time
during the observation period do not contribute to
the estimate of the association between exposure
and outcome, but the inclusion of such participants
can improve control for confounding by age. Our
primary analysis was restricted to participants who
were exposed to inflammatory stimuli at least once
during the follow-up period, but the analysis was
repeated to include all cases in order to ensure that
the estimates did not vary. Because the chance of
receiving a vaccination during the period immedi-
ately after a vascular event may have been different
from that during the remainder of the observation
period, we repeated the analysis by excluding from
the baseline period the three months before each
vaccination.
Deaths from cardiovascular disease are more
common in winter than in summer.
 
23
 
 Respiratory
infections occur more commonly in the winter
months, and influenza vaccine is usually adminis-
tered in the early winter. Therefore, a temporal as-
sociation between vascular events and respiratory
infections or influenza vaccination could be ob-
served even in the absence of a causal role. To inves-
tigate this possibility, we analyzed separately the
effect of respiratory tract infections acquired in
warm months (April through September) and in
cool months (October through March).
We estimated that the analysis of the risk of my-
ocardial infarction or stroke after influenza vacci-
nation could include around 20,000 participants
who had been exposed, a sample size sufficient to
provide more than 90 percent power at the 5 per-
cent level of significance to detect a rate ratio of 1.3
during the first three days after exposure.
A total of 61,556 adults with a first or subsequent
myocardial infarction were identified in the GPRD,
of whom 1495 were excluded because the date of the
myocardial infarction was uncertain. Of the remain-
ing 60,061 patients, 53,709 had had a first myocar-
dial infarction (median age at myocardial infarction,
72.3 years; interquartile range, 62.9 to 80.5; male
sex, 59.1 percent; mean duration of observation, 5.6
years), and 12,134 had had a recurrent myocardial
infarction (median age, 71.8 years; interquartile
range, 63.3 to 79.1; male sex, 68.8 percent; mean
duration of observation, 4.1 years). There were 5782
persons with no history of myocardial infarction be-
fore the observation period who had two myocar-
dial infarctions within the observation period and
were included in both groups of participants. Of a
total of 56,018 adults with a first or subsequent
stroke who were identified in the GPRD, 861 were
excluded because of an unlikely date of stroke. Of
the remaining 55,157 patients, 50,766 had had a
first stroke (median age at stroke, 78.3 years; inter-
quartile range, 70.2 to 85.0; male sex, 43.8 per-
cent; mean duration of observation, 5.3 years), and
12,804 had had a subsequent stroke (median age,
78.8 years, interquartile range, 71.2 to 85.0; male
sex, 46.6 percent; mean duration of observation,
3.5 years). Subsequently, 13,099 patients with my-
ocardial infarction and 12,572 with stroke were ex-
cluded from one or more of the vaccine analyses
because of uncertain vaccination dates.
Only persons who were exposed to either vac-
cine or infection were included in the primary analy-
sis (Tables 1 and 2). The proportion of participants
with a first myocardial infarction or stroke who were
exposed to the stimuli of interest ranged from 9 per-
cent (those with stroke who were exposed to pneu-
mococcal vaccine) to 44 percent (those with stroke
who were exposed to a systemic respiratory tract
infection). The numbers of patients exposed who
had a first myocardial infarction or a first stroke and
the age-adjusted incidence ratios of a first myocar-
dial infarction or stroke after vaccination and acute
infection are shown in Table 1.
There was no increase in the rate of a first myo-
cardial infarction or stroke in the periods after vac-
cination. However, the rates of both myocardial in-
farction and stroke were substantially higher after
a diagnosis of an acute respiratory tract infection.
The rates were highest during the first three days
after exposure (i.e., an increase by a factor of nearly
five for myocardial infarction and a factor of slight-
ly more than three for stroke) and then fell during
the following weeks. The rates also increased after
a diagnosis of urinary tract infection.
For second myocardial infarctions or second
strokes, again, there was no increase in the rate of
events after vaccination (Table 2). The rate of sec-
ond events after a diagnosis of respiratory tract in-
fection or urinary tract infection followed patterns
similar to those observed for first events, although
the effect estimates were slightly lower.
results
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secondary analyses
 
Controlling for age in two-year age groups, includ-
ing participants who had not been exposed, and ex-
cluding the three months before each vaccination
made no material difference to the effect estimates
(data not shown). There were slightly more partic-
ipants with a first myocardial infarction (21,957) or
stroke (20,023) in winter than in summer (20,154
participants with a first myocardial infarction, and
19,148 with a first stroke). However, the signifi-
cant graded effect of respiratory tract infection re-
mained when the analysis was restricted to events
occurring in the summer.
This study shows that acute lower respiratory tract
infections and urinary tract infections are associat-
discussion
 
* The numbers of participants exposed to each type of vaccination or infection are shown in parentheses for each exposure. These include a 
small number who had a recorded myocardial infarction or stroke on the day of exposure that was not included in the analysis, because the 
events may have been recorded retrospectively. Incidence during the baseline period served as the reference category. IR denotes age-adjusted 
 
incidence ratio, and CI confidence interval. Participants may appear within more than one category.
 
Table 1. Age-Adjusted Incidence Ratios of a First Myocardial Infarction and a First Stroke in Risk Periods after Exposure to Vaccination
or Infection.*
Outcome and 
Risk Period
Influenza Vaccination 
(N=20,486)
Tetanus Vaccination 
(N=7966)
Pneumococcal 
Vaccination 
(N=5925)
Systemic Respiratory 
Tract Infection 
(N=20,921)
Urinary Tract Infection 
(N=10,448)
 
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR 
(95% CI)
 
Myocardial infarction
 
1–3 days 77 0.75
(0.60–0.94)
12 1.10
(0.62–1.92)
4 0.49
(0.19–1.32)
322 4.95
(4.43–5.53)
58 1.66
(1.28–2.14)
4–7 days 94 0.68
(0.56–0.84)
17 1.16
(0.72–1.87)
12 1.11
(0.63–1.96)
276 3.20 
(2.84–3.60)
75 1.61 
(1.28–2.02)
8–14 days 176 0.73 
(0.63–0.85)
25 0.97 
(0.66–1.44)
23 1.22
(0.81–1.84)
422 2.81
(2.54–3.09)
100 1.22 
(1.00–1.49)
15–28 days 417 0.87 
(0.79–0.96)
46 0.89 
(0.66–1.19)
43 1.15 
(0.85–1.55)
576 1.95 
(1.79–2.12)
217 1.32 
(1.16–1.52)
29–91 days 2,154 1.03 
(0.98–1.08)
253 1.07 
(0.94–1.21)
177 1.10 
(0.95–1.28)
1,658 1.40 
(1.33–1.48)
820 1.23 
(1.14–1.33)
Baseline
period
17,533 1.00 7605 1.00 5662 1.00 17,099 1.00 9079 1.00 
 
Influenza Vaccination 
(N=19,063)
Tetanus Vaccination 
(N=6155) 
Pneumococcal 
Vaccination 
(N=4416)
Systemic Respiratory 
Tract Infection 
(N=22,400)
Urinary Tract Infection 
(N=14,603)
 
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR 
(95% CI)
 
Stroke
 
1– 3 days 76 0.77
(0.61–0.96)
11 1.33
(0.74–2.41)
9 1.29
(0.67–2.49)
244 3.19 
(2.81–3.62)
152 2.72 
(2.32–3.20)
4–7 days 95 0.72
(0.59–0.88)
15 1.36 
(0.82–2.26)
10 1.08 
(0.58–2.01)
237 2.34 
(2.05–2.66)
158 2.12 
(1.81–2.48)
8–14 days 194 0.84
(0.73–0.96)
15 0.77
(0.46–1.28)
19 1.18 
(0.75–1.85)
368 2.09
(1.89–2.32)
245 1.89 
(1.65–2.13)
15–28 days 409 0.88
(0.80–0.97)
40 1.02
(0.74–1.39)
29 0.90 
(0.63–1.30)
561 1.68 
(1.54–1.82)
445 1.71 
(1.55–1.88)
29–91 days 2,051 1.01
(0.96–1.06)
209 1.15
(1.00–1.32)
160 1.15 
(0.98–1.35)
1,650 1.33 
(1.26–1.40)
1,250 1.22 
(1.15–1.30)
Baseline
period
16,188 1.00 5853 1.00 4184 1.00 18,056 1.00 12,164 1.00 
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 19, 2014. For personal use only. No other uses without permission. 
 Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
 n engl j med 
 
351;25
 
www.nejm.org december 
 
16
 
, 
 
2004
 
The
 
 new england journal 
 
of
 
 medicine
 
2616
 
ed with a transient increase in the risk of a vascular
event. The effect is seen for a first or a subsequent
myocardial infarction or stroke and is most marked
in the few days after infection. These findings, based
on a very large set of data, support the link between
acute infection and the risk of a vascular event, iden-
tify the magnitude of the association and its resolu-
tion over time, and offer insight into the factors that
may determine the timing of acute vascular events.
No increase in the event rate was detected after in-
fluenza, tetanus, and pneumococcal vaccines.
In a study of the risk of vascular events after in-
flammatory stimuli, the potential for confounding
is great, because participants who are vaccinated or
in whom infections develop may differ from those
who are not vaccinated or do not have infections.
The advantage of the case-series method is that the
influence of factors that vary among the participants,
 
* The numbers of participants exposed to each type of vaccination or infection are shown in parentheses for each exposure. These include a 
small number who had a recorded myocardial infarction or stroke on the day of exposure that was not included in the analysis, because the 
events may have been recorded retrospectively. Incidence during the baseline period served as the reference category. IR denotes age-adjusted 
 
incidence ratio, and CI confidence interval. 
 
Table 2. Age-Adjusted Incidence Ratios of a Recurrent Myocardial Infarction or Stroke during Risk Periods after Exposure to Vaccination 
or Infection.*
Outcome and 
Risk Period
Influenza Vaccination 
(N=4010)
Tetanus Vaccination 
(N=1889)
Pneumococcal 
Vaccination 
(N=1686)
Systemic Respiratory 
Tract Infection 
(N=5259)
Urinary Tract Infection 
(N=2408)
 
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR 
(95% CI)
 
Myocardial infarction
 
1–3 days 11 0.34
(0.19–0.61)
1 0.42
(0.06–2.87)
2 0.70
(0.18–2.81)
61 3.14
(2.43–4.05)
12 1.38
(0.78–2.43)
4–7 days 34 0.77
(0.55–1.09)
2 0.63
(0.16–2.51)
2 0.53
(0.13–2.10)
59 2.26
(1.74–2.93)
18 1.55
(0.97–2.47)
8–14 days 71 0.93
(0.73–1.18)
7 1.24
(0.59–2.62)
9 1.34
(0.69–2.60)
78 1.71
(1.36–2.14)
35 1.72 
(1.23–2.42)
15–28 days 146 0.97
(0.82–1.16)
7 0.61 
(0.29–1.28)
14 1.05
(0.62–1.79)
131 1.45
(1.21–1.73)
51 1.25
(0.94–1.66)
29–91 days 607 0.97
(0.88–1.06)
58 1.04
(0.79–1.36)
79 1.42
(1.12–1.79)
488 1.38
(1.24–1.52)
172 1.04
(0.88–1.23)
Baseline
period
3131 1.00 1812 1.00 1578 1.00 4339 1.00 2097 1.00 
 
Influenza Vaccination 
(N=4139)
Tetanus Vaccination 
(N=1355)
Pneumococcal 
Vaccination 
(N=1117)
Systemic Respiratory 
Tract Infection 
(N=6016)
Urinary Tract Infection 
(N=4273)
 
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR
(95% CI)
No. of 
Cases
IR 
(95% CI)
 
Stroke
 
1–3 days 19 0.56
(0.35–0.89)
3 2.05 
(0.66–6.41)
2 1.01 
(0.25–4.04)
70 2.57 
(2.03–3.27)
37 1.65
(1.19–2.28)
4–7 days 33 0.74
(0.52–1.05)
1 0.49 
(0.07–3.52)
3 1.13 
(0.36–3.52)
80 2.23
(1.78–2.80)
52 1.72
(1.31–2.28)
8–14 days 56 0.72 
(0.55–0.94)
2 0.54 
(0.13–2.20)
3 0.64 
(0.21–2.00)
94 1.51
(1.23–1.86)
72 1.35 
(1.06–1.72)
15–28 days 105 0.69 
(0.57–0.85)
5 0.63 
(0.26–1.55)
10 1.06 
(0.57–2.00)
145 1.27 
(1.07–1.50)
124 1.15 
(0.96–1.39)
29–91 days 516 0.79 
(0.71–0.87)
38 0.96
(0.67–1.37)
46 0.99 
(0.72–1.35)
501 1.27 
(1.15–1.41)
470 1.16 
(1.04–1.29)
Baseline
period
3396 1.00 1301 1.00 1053 1.00 4617 1.00 3472 1.00 
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such as the baseline cardiovascular risk, is removed,
because within-person comparisons are performed.
The null hypothesis was that the event rates stay
relatively constant with time and are not influenced
by discrete external stimuli such as acute infections.
Our finding of a substantial but short-lived increase
in the incidence of vascular events after acute infec-
tion shows that the risk of a cardiovascular event
fluctuates, and it is highly suggestive of a causal
role for acute infections in triggering cardiovascu-
lar events.
There has been one previous case–control study
of an association between acute respiratory tract
infection and myocardial infarction that was based
on the GPRD.
 
24
 
 The study included 475 persons
who had a respiratory tract infection within the 12
months preceding a myocardial infarction and
found that the risk of respiratory infection was in-
creased by approximately a factor of three during
the 10 days before the myocardial infarction but
found no significant association with urinary tract
infection. We confirmed this finding in a much larg-
er group (more than 20,000 participants exposed to
respiratory tract infections), using a different study
design. In our study, the effect was similar for stroke,
for both first and subsequent events, and, unlike the
earlier smaller study, our study showed an increased
risk after urinary tract infection. This finding is im-
portant, because it suggests that the effect of infec-
tions on cardiovascular risk may be generic and is
not linked to specific types of infection. Further-
more, although certain cardiac presentations might
be misdiagnosed as respiratory tract infection, this
seems highly unlikely to be the case for urinary tract
infection.
Our study was based on routine clinical data, and
a potential weakness may be related to the quality
of the data. However, the diagnosis of myocardial
infarction in the GPRD has been examined in a sub-
group of patients on the basis of electrocardio-
graphic findings, elevated levels of cardiac enzymes,
features of the history, or the receipt of fibrinolytic
therapy, and the diagnosis was confirmed in more
than 90 percent of the recorded cases.
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 A diag-
nosis of stroke in the GPRD was checked by a re-
view of hospital records and confirmed in 89 per-
cent (78 of 88) of cases, and the incidence rates for
stroke are similar to estimates obtained from other
sources.
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 The vaccination data recorded in the
GPRD are likely to be of high quality, because there
is close agreement between the prescribing data in
this database and national data from the Prescrip-
tion Pricing Authority; moreover, general practi-
tioners have a financial incentive to record vaccines
given.
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The incidence rates of myocardial infarction or
stroke did not return fully to the baseline level with-
in the three-month risk period after infection, a re-
sult that might be due to a greater likelihood that a
diagnosis was recorded, but the magnitude of the
residual increase was small (incidence ratio, 1.2 to
1.4) and even after taking this increase into account,
the greatly increased rates seen in the period soon
after infection remained significantly elevated. The
effects of infection were not explained by seasonal
patterns of exposure and vascular events.
One limitation of the study is that we did not
know precisely the date of onset of infections but,
rather, used the date of diagnosis. However, the ma-
jority of patients, even those with upper respiratory
tract infections, visit their general practitioner with-
in three days after the onset of symptoms,
 
28
 
 so that
we are unlikely to have underestimated the duration
of the increase in the risk of vascular events by more
than a few days. An advantage of looking at vacci-
nation as a stimulus is that we knew the date of ex-
posure, but we saw no effect of vaccination on risk,
probably because both the magnitude and the du-
ration of the inflammation induced by vaccination
are small,
 
15
 
 as compared with naturally occurring
infection.
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 The small protective effect seen after
vaccination may have been due to the administra-
tion of vaccination when people were in periods of
relatively good health.
The finding that two very different infectious pro-
cesses in different organ systems are associated with
a large but transient increase in the risk of cardio-
vascular events lends strong support to the concept
that systemic inflammation itself alters the proba-
bility of the occurrence of a vascular event. The al-
ternative explanation that there is some common
acute precipitant of infection and vascular events
seems less likely. We do not know whether the tran-
sient increase in risk is due to a short-term alteration
of endothelial function or to other mechanisms,
such as changes in plaque composition, white-cell
activation, dehydration, or bed rest. Clearly, how-
ever, it will now be important to establish the mech-
anisms of and implications for prevention.
Our observations offer insight into the factors
that may determine the timing of the onset of a vas-
cular event in persons who have had a fairly stable
degree of atherosclerosis for many years. The mild
transient inflammation and associated suppression
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of endothelium-dependent relaxation induced by
vaccination
 
15
 
 does not appear to translate into a de-
tectable increase in the risk of vascular events.
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